Related Experiment Video
Updated: Jun 25, 2025
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
9.0K
Navigating the complexities of drug development for inflammatory bowel disease
Sailish Honap1,2,3, Vipul Jairath4,5,6, Silvio Danese7
1Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK. shonap@nhs.net.
Nature Reviews. Drug Discovery
|May 22, 2024
Summary
Novel approaches in machine learning and tissue engineering can improve preclinical drug development for inflammatory bowel disease (IBD). Innovative clinical trial designs are also crucial for advancing IBD therapies.
Area of Science:
- Immunology
- Gastroenterology
- Biotechnology
Background:
- Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a complex immune-mediated condition with limited treatment efficacy from current therapies.
- A plateau in therapeutic advancements necessitates the identification of new drug targets and companion biomarkers for patient stratification.
- High attrition rates in preclinical stages and declining recruitment in clinical trials impede the development of novel IBD treatments.
Purpose of the Study:
- To explore the potential of machine learning and tissue engineering in enhancing preclinical drug development for IBD.
- To identify strategies for overcoming challenges in clinical trial progression, including recruitment and design.
- To propose innovative approaches for accelerating the development of more effective IBD therapies.
Main Methods:
- Review of current therapeutic landscape and challenges in IBD drug development.
- Examination of machine learning and tissue engineering applications in preclinical research.
- Analysis of factors affecting clinical trial progression and recruitment.
- Assessment of innovative clinical trial designs, endpoint harmonization, and digital technology integration.
Main Results:
- Machine learning and tissue engineering offer promising avenues to improve preclinical IBD research and reduce attrition rates.
- Reconfiguring clinical trial designs, standardizing endpoints, and utilizing digital tools can accelerate the progression of novel IBD agents.
- Addressing challenges at each stage of drug development is key to achieving incremental gains.
Conclusions:
- Integrating advanced preclinical technologies and optimizing clinical trial methodologies are essential for advancing IBD therapeutics.
- A multi-faceted approach, from bench to bedside, is required to overcome current limitations in IBD drug development.
- Harnessing technological and methodological innovations can lead to more effective treatments for patients with inflammatory bowel disease.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115